PCM
EVGN icon

Penserra Capital Management’s Evogene EVGN Stock Holding History

Penserra Capital Management’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-293
Closed -$7.35K – 991
2016
Q1 		$7.35K Buy
293
+97
+49% +$6.66K 0.72% 40
2015
Q4 		$16K Buy
+196
New +$14.6K ﹤0.01% 436

Other funds holding EVGN

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Penserra Capital Management's EVGN Position: Q2 2016 in Review

Penserra Capital Management sold out of Evogene (EVGN) in Q2 2016, closing a stake of 293 shares — an estimated $7.35K sold.

Penserra Capital Management first reported a position in EVGN in Q4 2015 and held it in 2 quarters. The position peaked at $16K in Q4 2015. 18 funds tracked by Wall St. Rank hold EVGN as of Q2 2016.

  • Penserra Capital Management reported no remaining Evogene position as of Q2 2016 after selling out during the quarter.
  • Penserra Capital Management sold 293 Evogene shares in Q2 2016, an estimated $7.35K.
  • Penserra Capital Management first reported a position in Evogene in Q4 2015 and held it in 2 quarters.
  • Penserra Capital Management's Evogene position peaked at $16K in Q4 2015.
  • 18 funds tracked by Wall St. Rank held Evogene as of Q2 2016.

Based on Penserra Capital Management's 13F filing for Q2 2016, filed 9 Aug 2016.